CD274 and metastatic neoplasm: The objective of this study was to evaluate the comparative efficacy, safety, and tolerability of cemiplimab monotherapy versus other immune-oncology monotherapies among patients with locally advanced or metastatic NSCLC with PD-L1 expression ⩾50% who had not received prior systemic therapy for advanced/metastatic disease.